Literature DB >> 9766650

NUP98-HOXD13 gene fusion in therapy-related acute myelogenous leukemia.

S Z Raza-Egilmez1, S N Jani-Sait, M Grossi, M J Higgins, T B Shows, P D Aplan.   

Abstract

A novel chromosomal translocation, t(2;11)(q31;p15), was identified in a patient with therapy-related acute myelogenous leukemia (t-AML). Fluorescence in situ hybridization experiments mapped the breakpoint near NUP98; Southern blot analysis demonstrated that the nucleoporin gene NUP98 was disrupted by this translocation. We used rapid amplification of cDNA ends to identify a chimeric mRNA. An in-frame, chimeric mRNA that fused NUP98 sequences to the homeobox gene HOXD13 was cloned; the predicted fusion protein contains both the GLFG repeats from NUP98 as well as the homeodomain from HOXD13. The NUP98-HOXD13 fusion is structurally similar to the NUP98-HOXA9 fusion previously identified in patients with AML, leading to the speculation that NUP98-homeobox gene fusions may be oncogenic. Moreover, this report, along with a recent study that demonstrated NUP98-DDX10 fusions in patients with t-AML, raises the possibility that NUP98 may be a previously unsuspected target for chromosomal translocations in patients with t-AML.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9766650

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

1.  Involvement of the NUP98 gene in a chromosomal translocation t(11;20)(p15;q11.2) in a patient with acute monocytic leukemia (FAB-M5b).

Authors:  N Kakazu; I Shinzato; Y Arai; S Gotoh; A Matsushita; T Ishikawa; K Nagai; T Takahashi; T Ohno; T Tsuchiya; M Ohki; T Abe
Journal:  Int J Hematol       Date:  2001-07       Impact factor: 2.490

2.  Differential and common leukemogenic potentials of multiple NUP98-Hox fusion proteins alone or with Meis1.

Authors:  Nicolas Pineault; Carolina Abramovich; Hideaki Ohta; R Keith Humphries
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

Review 3.  NUP98 fusion in human leukemia: dysregulation of the nuclear pore and homeodomain proteins.

Authors:  Takuro Nakamura
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

4.  Chromatin modifications induced by PML-RARalpha repress critical targets in leukemogenesis as analyzed by ChIP-Chip.

Authors:  Claudia Hoemme; Abdul Peerzada; Gerhard Behre; Yipeng Wang; Michael McClelland; Kay Nieselt; Matthias Zschunke; Christine Disselhoff; Shuchi Agrawal; Fabienne Isken; Nicola Tidow; Wolfgang E Berdel; Hubert Serve; Carsten Müller-Tidow
Journal:  Blood       Date:  2007-11-16       Impact factor: 22.113

5.  NUP98-HOXA9 expression in hemopoietic stem cells induces chronic and acute myeloid leukemias in mice.

Authors:  E Kroon; U Thorsteinsdottir; N Mayotte; T Nakamura; G Sauvageau
Journal:  EMBO J       Date:  2001-02-01       Impact factor: 11.598

Review 6.  NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights.

Authors:  Sheryl M Gough; Christopher I Slape; Peter D Aplan
Journal:  Blood       Date:  2011-09-26       Impact factor: 22.113

7.  Genomic analysis of fibrolamellar hepatocellular carcinoma.

Authors:  Lei Xu; Florette K Hazard; Anne-Flore Zmoos; Nadine Jahchan; Hassan Chaib; Phillip M Garfin; Arun Rangaswami; Michael P Snyder; Julien Sage
Journal:  Hum Mol Genet       Date:  2014-08-13       Impact factor: 6.150

8.  The fusion partner specifies the oncogenic potential of NUP98 fusion proteins.

Authors:  Jesslyn Saw; David J Curtis; Damian J Hussey; Alexander Dobrovic; Peter D Aplan; Christopher I Slape
Journal:  Leuk Res       Date:  2013-09-21       Impact factor: 3.156

9.  NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia.

Authors:  Ying-Wei Lin; Christopher Slape; Zhenhua Zhang; Peter D Aplan
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

10.  HOXD13 methylation status is a prognostic indicator in breast cancer.

Authors:  Zhenbin Zhong; Ming Shan; Ji Wang; Tong Liu; Bingshu Xia; Ming Niu; Yanlv Ren; Da Pang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.